<p>StockNews.com 的分析师在周一发布的研究报告中开始覆盖 Cytosorbents（NASDAQ:CTSO - 获取免费报告）的股票。该公司对这家医疗研究公司的股票给予了 “持有” 评级。</p>
<p>Cytosorbents 最近成为其他多份研究报告的主题。HC Wainwright 在 11 月 11 日的报告中重申了 “中性” 评级，并对 Cytosorbents 的股票设定了 1.00 美元的目标价。D. Boral Capital 在 2 月 25 日的报告中重申了 “买入” 评级，并对 Cytosorbents 的股票设定了 10.00 美元的目标价。两位研究分析师对该股票给予了持有评级，两位给予了买入评级，还有一位给予了强烈买入评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 4.67 美元。</p>
<p><strong>阅读我们对 Cytosorbents 的最新股票分析</strong></p>
<h2>Cytosorbents 股价下跌 3.8%</h2>
<p>Cytosorbents 股票周一开盘价为 1.01 美元。该公司的市值为 5523 万美元，市盈率为 -2.81，贝塔值为 0.78。Cytosorbents 的 12 个月最低价为 0.70 美元，最高价为 1.61 美元。该公司的 50 日移动平均价格为 1.05 美元，200 日移动平均价格为 1.05 美元。公司的流动比率为 1.97，速动比率为 1.58，债务与股本比率为 1.06。</p>
<h2>Cytosorbents 的机构交易</h2>
<p>最近，一些对冲基金和其他机构投资者对该公司的持仓进行了调整。Millennium Management LLC 在第四季度收购了 Cytosorbents 的新股份，价值约 30,000 美元。Northern Trust Corp 在第四季度将其在 Cytosorbents 的持股增加了 22.3%。Northern Trust Corp 目前拥有 91,560 股该医疗研究公司的股票，价值 83,000 美元，此前在上个季度又购买了 16,701 股。Avenir Corp 在第四季度将其在 Cytosorbents 的持股增加了 4.0%。Avenir Corp 目前拥有 3,093,946 股该医疗研究公司的股票，价值 2,815,000 美元，此前在上个季度又购买了 118,387 股。Raymond James Financial Inc. 在第四季度收购了 Cytosorbents 的新股份，价值约 99,000 美元。最后，Renaissance Technologies LLC 在第四季度将其在 Cytosorbents 的持股增加了 10.6%。Renaissance Technologies LLC 目前拥有 88,020 股该医疗研究公司的股票，价值 80,000 美元，此前在上个季度又购买了 8,400 股。机构投资者和对冲基金持有该公司 32.87% 的股票。</p>
<h2>关于 Cytosorbents</h2>
<p>(获取免费报告)</p>
<p>Cytosorbents Corporation 从事医疗设备的研究、开发和商业化，其血液净化技术平台结合了专有的吸附剂和多孔聚合物技术，业务遍及美国、德国及国际市场。其旗舰产品为 CytoSorb，一种用于脓毒症治疗的体外细胞因子吸附器，作为辅助治疗，适用于其他重症护理应用、预防和治疗围手术期并发症，以及维持或增强从供体处获取的固体器官的质量以进行器官移植；并提供 VetResQ，一种用于动物脓毒症、胰腺炎和其他危重病症的辅助治疗设备。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过 Cytosorbents</li>
<li>卖空：如何做空股票</li>
<li>机构投资者在这四只股票上下注 10 亿美元——你应该买吗？</li>
<li>投资旅游股票的好处</li>
<li>在关税冲击市场时，必须购买的股票和必须避免的股票</li>
<li>如何一步步购买便宜股票</li>
<li>这四只科技 ETF 刚刚触及 50 日低点——现在是买入时机吗？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Cytosorbents 吗？</h2>
<p>在你考虑 Cytosorbents 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄推荐给客户的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Cytosorbents 并不在名单上。</p>
<p>虽然 Cytosorbents 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CTSO

<p>StockNews.com 在周一的一份研究报告中开始对 CytoSorbents 的股票进行覆盖。他们对该股票给予了 “持有” 评级</p>

<p>Analysts at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a research note issued on Monday. The firm set a &#34;hold&#34; rating on the medical research company's stock.</p>
<div class="lb-trans"><p>StockNews.com 的分析师在周一发布的研究报告中开始覆盖 Cytosorbents（NASDAQ:CTSO - 获取免费报告）的股票。该公司对这家医疗研究公司的股票给予了 “持有” 评级。</p>
</div><p>CTSO has been the subject of a number of other research reports. HC Wainwright reiterated a &#34;neutral&#34; rating and issued a $1.00 price objective on shares of Cytosorbents in a report on Monday, November 11th. D. Boral Capital reiterated a &#34;buy&#34; rating and issued a $10.00 price objective on shares of Cytosorbents in a report on Tuesday, February 25th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $4.67.</p>
<div class="lb-trans"><p>Cytosorbents 最近成为其他多份研究报告的主题。HC Wainwright 在 11 月 11 日的报告中重申了 “中性” 评级，并对 Cytosorbents 的股票设定了 1.00 美元的目标价。D. Boral Capital 在 2 月 25 日的报告中重申了 “买入” 评级，并对 Cytosorbents 的股票设定了 10.00 美元的目标价。两位研究分析师对该股票给予了持有评级，两位给予了买入评级，还有一位给予了强烈买入评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 4.67 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Cytosorbents</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Cytosorbents 的最新股票分析</strong></p>
</div><h2>Cytosorbents Trading Down 3.8 %</h2>
<div class="lb-trans"><h2>Cytosorbents 股价下跌 3.8%</h2>
</div><p>Shares of Cytosorbents stock opened at $1.01 on Monday. The firm has a market capitalization of $55.23 million, a PE ratio of -2.81 and a beta of 0.78. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.61. The firm's 50-day moving average price is $1.05 and its 200 day moving average price is $1.05. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06.</p>
<div class="lb-trans"><p>Cytosorbents 股票周一开盘价为 1.01 美元。该公司的市值为 5523 万美元，市盈率为 -2.81，贝塔值为 0.78。Cytosorbents 的 12 个月最低价为 0.70 美元，最高价为 1.61 美元。该公司的 50 日移动平均价格为 1.05 美元，200 日移动平均价格为 1.05 美元。公司的流动比率为 1.97，速动比率为 1.58，债务与股本比率为 1.06。</p>
</div><h2>Institutional Trading of Cytosorbents</h2>
<div class="lb-trans"><h2>Cytosorbents 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC acquired a new stake in shares of Cytosorbents during the 4th quarter worth approximately $30,000. Northern Trust Corp increased its holdings in shares of Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after buying an additional 16,701 shares during the last quarter. Avenir Corp increased its holdings in shares of Cytosorbents by 4.0% during the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company's stock worth $2,815,000 after buying an additional 118,387 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Cytosorbents during the 4th quarter worth approximately $99,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock worth $80,000 after buying an additional 8,400 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company's stock.</p>
<div class="lb-trans"><p>最近，一些对冲基金和其他机构投资者对该公司的持仓进行了调整。Millennium Management LLC 在第四季度收购了 Cytosorbents 的新股份，价值约 30,000 美元。Northern Trust Corp 在第四季度将其在 Cytosorbents 的持股增加了 22.3%。Northern Trust Corp 目前拥有 91,560 股该医疗研究公司的股票，价值 83,000 美元，此前在上个季度又购买了 16,701 股。Avenir Corp 在第四季度将其在 Cytosorbents 的持股增加了 4.0%。Avenir Corp 目前拥有 3,093,946 股该医疗研究公司的股票，价值 2,815,000 美元，此前在上个季度又购买了 118,387 股。Raymond James Financial Inc. 在第四季度收购了 Cytosorbents 的新股份，价值约 99,000 美元。最后，Renaissance Technologies LLC 在第四季度将其在 Cytosorbents 的持股增加了 10.6%。Renaissance Technologies LLC 目前拥有 88,020 股该医疗研究公司的股票，价值 80,000 美元，此前在上个季度又购买了 8,400 股。机构投资者和对冲基金持有该公司 32.87% 的股票。</p>
</div><h2>About Cytosorbents</h2>
<div class="lb-trans"><h2>关于 Cytosorbents</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.</p>
<div class="lb-trans"><p>Cytosorbents Corporation 从事医疗设备的研究、开发和商业化，其血液净化技术平台结合了专有的吸附剂和多孔聚合物技术，业务遍及美国、德国及国际市场。其旗舰产品为 CytoSorb，一种用于脓毒症治疗的体外细胞因子吸附器，作为辅助治疗，适用于其他重症护理应用、预防和治疗围手术期并发症，以及维持或增强从供体处获取的固体器官的质量以进行器官移植；并提供 VetResQ，一种用于动物脓毒症、胰腺炎和其他危重病症的辅助治疗设备。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Cytosorbents</li>
<li>Short Selling: How to Short a Stock</li>
<li>Institutional Investors Bet $1B on These 4 Stocks—Should You?</li>
<li>Investing in Travel Stocks Benefits</li>
<li>One Must-Buy Stock and One to Avoid as Tariffs Shake the Market</li>
<li>How to Buy Cheap Stocks Step by Step</li>
<li>These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Cytosorbents</li>
<li>卖空：如何做空股票</li>
<li>机构投资者在这四只股票上下注 10 亿美元——你应该买吗？</li>
<li>投资旅游股票的好处</li>
<li>在关税冲击市场时，必须购买的股票和必须避免的股票</li>
<li>如何一步步购买便宜股票</li>
<li>这四只科技 ETF 刚刚触及 50 日低点——现在是买入时机吗？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Cytosorbents Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cytosorbents 吗？</h2>
</div><p>Before you consider Cytosorbents, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Cytosorbents 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytosorbents wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄推荐给客户的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Cytosorbents 并不在名单上。</p>
</div><p>While Cytosorbents currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cytosorbents 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

StockNews.com 开始对 CytoSorbents（纳斯达克股票代码：CTSO）进行报道